Want to see JP:4563 full AI Analyst Report?

AnGes (4563) Price & Analysis

1 Followers

4563 Stock Chart & Stats

¥47.00

¥0.00(0.00%)

At close: Jul 27 4:00 PM EDT

¥47.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥44.00 - ¥120.00

Previous CloseN/A

Volume237.70K

Average Volume (3M)3.22M

Market Cap

¥18.75B

Enterprise Value¥18.05B

Total Cash (Recent Filing)¥835.88M

Total Debt (Recent Filing)¥688.34M

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-14.10

Shares Outstanding398,835,540

10 Day Avg. Volume1,701,110

30 Day Avg. Volume3,216,076

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)7.04

Price to Sales (P/S)24.76

P/FCF Ratio-3.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Accelerating Revenue GrowthSustained revenue acceleration signals improving commercial traction for AnGes’ programs and strengthens negotiation leverage for licensing deals. Over 2-6 months this trend can translate into larger milestone potential, better partner interest, and a reduced reliance on short-term dilutive financing.

Low Leverage Provides FlexibilityA low-debt balance sheet gives the company time and flexibility to advance clinical programs without immediate refinancing pressure. This durable advantage lowers default risk, preserves optionality for partnerships or licensing, and extends the window to reach value-driving milestones.

Pipeline Monetization Business ModelFocusing on licensing and collaboration monetization aligns cash inflows with development milestones, enabling non-dilutive or staged funding. Structurally this model can de-risk programs, convert R&D into recurring milestone/royalty revenue, and leverage partners' commercialization strengths.

Bears Say

Deep Negative Operating And Free Cash FlowPersistent cash burn is a structural vulnerability that forces repeated external financing or partner-dependent funding. Over months this raises dilution and execution risk, constrains investment in multiple programs, and increases the chance of program delays if capital access tightens.

Large Operating Losses And Negative Net IncomeOngoing operating losses indicate the business is not yet self-sustaining and limits internal ability to scale R&D or commercialization. Structurally, this keeps the firm dependent on partners or markets for funding and extends the timeline to breakeven, increasing execution risk.

Eroding Equity And Total AssetsDeclining assets and equity erode the balance sheet cushion, reducing borrowing capacity and the ability to absorb setbacks. Over a medium-term horizon this heightens funding vulnerability, may force unfavorable financing terms, and can limit strategic optionality.

4563 FAQ

What was AnGes Inc’s price range in the past 12 months?

AnGes Inc lowest stock price was ¥44.00 and its highest was ¥120.00 in the past 12 months.

What is AnGes Inc’s market cap?

AnGes Inc’s market cap is ¥18.75B.

When is AnGes Inc’s upcoming earnings report date?

AnGes Inc’s upcoming earnings report date is Aug 07, 2026 which is in 6 days.

How were AnGes Inc’s earnings last quarter?

AnGes Inc released its earnings results on May 08, 2026. The company reported -¥2.74 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.74.

Is AnGes Inc overvalued?

According to Wall Street analysts AnGes Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AnGes Inc pay dividends?

AnGes Inc does not currently pay dividends.

What is AnGes Inc’s EPS estimate?

AnGes Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AnGes Inc have?

AnGes Inc has 398,835,540 shares outstanding.

What happened to AnGes Inc’s price movement after its last earnings report?

AnGes Inc reported an EPS of -¥2.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.923%.

Which hedge fund is a major shareholder of AnGes Inc?

Currently, no hedge funds are holding shares in JP:4563

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AnGes Inc

AnGes, Inc. (4563) is a Japanese biotechnology company focused on developing and commercializing nucleic-acid–based medicines and gene therapies. The company’s activities center on research and development, clinical development, regulatory work, and potential out-licensing of drug candidates, with a portfolio historically associated with DNA plasmid–based therapeutics and other genetic medicine approaches. null